Trial Profile
Part 1 of a three part study- A Study to Investigate the Safety, Tolerability and Pharmacokinetics, of AB-729 Administered by Subcutaneous Injection to Healthy Subjects (part 1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Imdusiran (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arbutus Biopharma
- 10 Nov 2021 Results published in an Arbutus Biopharma Media Release
- 04 Nov 2021 According to an Arbutus Biopharma media release, the company will be presenting data from additional cohorts of this study at the upcoming AASLD medical conference.
- 02 Nov 2021 Planned End Date changed from 31 Aug 2022 to 2 Jun 2023.